GLP-1 receptor agonists have known satiety-promoting effects due to central action of the neuropeptide GLP-1 [1], with reduced activation of appetite- and reward-related brain areas in response to food [18]
Patients who are forced to switch from a brand name medication at one dose to a compounded version at a different dose may experience a temporary increase in GI side effects as their body adjusts to the new formulation
Cagrilintide exemplifies a modern approach to weight loss, emphasizing hormonal and neurological systems over simple calorie counting
The combination targets two distinct appetite pathways: amylin receptors controlling hedonic eating behavior and GLP-1 receptors regulating homeostatic energy balance, producing additive weight loss beyond either mechanism alone
In this regard, over the past 20 years, several clinical trials demonstrated the benefits of Se therapy, especially intravenous bolus administration, on clinical outcomes in patients with a critical illness [18]